-
CHRONIC ACHILLES TENDINOPATHYClinically proven to accelerate healing in soft-tissue structures such as tendons and ligaments. Used successfully by many of the world’s top athletes, including New Zealand's Dan Carter
-
CHRONIC WOUND MANAGEMENTClinically proven to heal hitherto non-healing venous leg ulcers.
Independant health economics analysis demonstrated a cost per QALY of –£7,696. Now available on NHS supply chain and NHS procurement
Company overview
Find out about our company history, its directors and it's commitment to clinical excellence.
Shop Synapse micro-current
Tendonworks is available at www.tendonworks.com and various approved retailers.
Accel-Heal is available on
NHS supply chain and
NHS procurement
Science
A repository of science relating to Synapse micro-current.
Welcome to Synapse micro-current.
Synapse Micro-current Ltd. is a leading medical technology based company specializing in developing and taking to market clinically proven medical devices to promote advanced tissue healing in a variety of different applications.
Incorporated in January 2003, Synapse focussed its efforts in the early years in refining and securing patents and IP rights to its micro-current technology. In 2007 Synapse was awarded ISO 9001 & ISO 13485 accreditation for the design and manufacture of its micro-current devices for medical and sports applications.
In 2009, independently conducted clinical trials demonstrated that
Accel-Heal® made significant reductions in wound size, exudate levels and pain in 95% of the trial patients who suffered from non-healing venous leg ulcers, with 38% achieving full closure.
The rigorous procurement exercise undertaken by NHS Shared Business Services (NHS SBS) resulted in Synapse Microcurrent being selected to feature on NHS SBS’s 2-year Innovative Wound Healing Technologies Framework Agreement. Over 50 companies competed with only 4 technologies being selected.
Accel-Heal® offers compelling evidence for its innovation, with independent supporting information, including clinical trials and health economics analysis demonstrating a QALY of – (minus) £7,696.
Latest News
July 2011
SYNAPSE MICROCURRENT LTD SEALS WOUNDCARE CONTRACT WITH NHS SBS
UK-based health technology company Synapse Microcurrent could be supplying its innovative Accel-Heal® wound management system to every NHS Trust in England. It has succeeded in its bid to be appointed onto a national Framework Agreement.
Kevin Pritchard, Director of Strategic Sourcing at NHS SBS said:
“The award of this new Framework Agreement realises an ambition for the organisation of partnering with suppliers who provide innovative products and services which deliver genuine advancements in care whilst contributing to cost management. With the estimated annual NHS cost of wound care at approximately £3 billion, any product which can demonstrate clear patient benefits in terms of advanced recovery, cost savings and productivity gains for the NHS is to be applauded.”
